Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05869-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Hematology, 2024. Verfasst von Christina-Nefeli Kontandreopoulou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) is characterized by disease- and treatment-related immunosuppression. Patients with CLL comprise a vulnerable population to coronavirus disease 2019 (COVID-19), while the protective effect of COVID-19 vaccination remains uncertain.We conducted a systematic review to evaluate published data reporting response to COVID-19 vaccination in patients with CLL. The primary outcome was the rate of seropositivity after full primary vaccination, while secondary outcomes were rates of positive neutralizing antibodies, cellular responses, and adverse events. Response after booster doses of vaccination was also evaluated.Twenty-three studies of full primary vaccination (12 CLL-specific with 1747 patients, 11 with mixed hematologic diseases including 1044 patients with CLL) with a total of 2791 patients, and eight studies on booster doses with 389 patients were included in the analysis. The serologic response varied between studies with a median of 55%. Where reported, the median neutralizing antibody response rate was 61.2% and the cellular response rate was 44.2%. Poor serologic response was noted in patients under active treatment with anti-CD20 monoclonal antibodies, BCL2, and BTK inhibitors.The present review highlights the substantially impaired humoral and cellular response to COVID-19 vaccination in patients with CLL with patients under active treatment being the most vulnerable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Internal Medicine, University of Patras Medical School, Rion, Greece. elina_knt@hotmail.com.
Zitieren
APA
Kontandreopoulou, C. N., Solomou, E. E., Kolorizos, E., & Diamantopoulos, P. T. (2024). Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-024-05869-8
Vancouver
Kontandreopoulou CN, Solomou EE, Kolorizos E, Diamantopoulos PT. Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia. Annals of Hematology. 2024. doi:10.1007/s00277-024-05869-8
BibTeX
@article{Kontandreopoulou2024,
author = {Kontandreopoulou, Christina-Nefeli and Solomou, Elena E and Kolorizos, Epaminondas and Diamantopoulos, Panagiotis T},
title = {Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05869-8}
}
EUVIMED